Quattro Micro MS-MS was developed for the analysis of 6-acetylmorphine (6-AM) in human urine specimens. The method was linear (R 2 = 0.9983) to 100 ng/mL, with no carryover at 200 ng/mL. Limits of quantification and detection were found to be 2 ng/mL. Interrun precision calculated as percent coefficient of variation (%CV) and evaluated by analyzing five specimens at 10 ng/mL over nine batches (n = 45) was 3.6%. Intrarun precision evaluated from 0 to 100 ng/mL ranged from 1.0 to 4.4%CV. Other opioids (codeine, morphine, oxycodone, oxymorphone, hydromorphone, hydrocodone, and norcodeine) did not interfere in the detection, quantification, or chromatography of 6-AM or the deuterated internal standard. The quantified values for 41 authentic human urine specimens previously found to contain 6-AM by a validated gas chromatography (GC)-MS method were compared to those obtained by the SPE-LC-MS-MS method. The SPE-LC-MS-MS procedure eliminates the human factors of specimen handling, extraction, and derivatization, thereby reducing labor costs and rework resulting from human error or technique issues. The time required for extraction and analysis was reduced by approximately 50% when compared to a validated 6-AM procedure using manual SPE and GC-MS analysis.
Introduction
Within the past few years, the purity of heroin has been increasing while its reported price in many areas is decreasing (1) . This has increased the appeal of heroin for new users as purer heroin can be inhaled rather than injected cutting down on the risk of syringe-born disease transmission and eliminating the social stigma attached to intravenous injection (2) . Many first time users also erroneously believe that snorting heroin can reduce the possibility for addiction. There is also an increase in the availability of black tar heroin especially in the Southwest United States (U.S.) near border cities with Mexico, where it enters the U.S. (3). The presence of tens of thousands of U.S. troops now serving in Afghanistan, the number one source for the world's heroin (4), is a major concern for military leaders because of their close proximity to heroin production and supply.
According to the most recent assessment of drug abuse and trafficking by the National Drug Threat Assessment, prescription opioid abuse is rising at an alarming rate and is currently the number one drug of choice for first-time abusers (5). In addition, officials in treatment facilities have reported opioid prescription abusers have begun to abuse heroin because it is typically cheaper, easier to obtain, and provides a more intense high. The assessment predicts that the greater availability of prescription narcotics will cause a concomitant rise in heroin abuse. As the number of wounded service members increases, so too does the use of medically valid opioid prescriptions and the associated risk of heroin abuse. Therefore, it is important to continue to develop sensitive and reliable methods for distinguishing between the use of heroin and other opioids.
In vivo, heroin is rapidly deacetylated to 6-acetylmorphine (6-AM), which is then further metabolized to morphine (6) . The presence of 6-AM in urine is used exclusively to substantiate heroin abuse as it is not metabolized from any other opioid including codeine and morphine (7, 8) . Historically, most opioid-positive results reported in the military are due to confirmed valid prescription use. A number of commercial immunoassay (IA) screening kits are available and have been evaluated for the detection of 6-AM to meet current requirements by the Department of Defense (DoD) for military drug testing procedures (9) . These DoD requirements include IA screening to be followed by gas chromatography-mass spectrometry (GC-MS) for confirmation of positives specimens. The use of GC-MS requires multiple preparatory steps, including drug metabolite extraction and derivatization. These procedures require hours of technician time, use of hazardous derivatizing reagents, production of chemical waste, and multiple steps at which human intervention is required.
An alternative technique for the analysis of 6-AM in urine is liquid chromatography-tandem mass spectrometry (LC-MS-MS) (10) . LC-MS-MS lends itself well to automation because derivatization is not necessary. We and others have previously reported on an automated system that combines solidphase extraction (SPE) and LC-MS-MS analysis that provides disposable SPE cartridges (11) (12) (13) . The U.S. Department of Health and Human Services (HHS) recently recognized LC-MS-MS as a viable technique for use in federally regulated workplace drug testing laboratories (14) .
The following report describes a method for the automated analysis of 6-AM in urine that demonstrates improved specimen handling and tracking which saves time and effort. The use of disposable SPE cartridges directly coupled to an LC-MS-MS eliminates the SPE cartridge as a source of cross-contamination between specimens. The forensic integrity of the analysis is improved by reducing human interaction with the specimens. Practical application of the method was demonstrated with a set of 41 authentic human urine specimens previously determined to contain 6-AM. These were analyzed in parallel with the SPE-LC-MS-MS method and the laboratory's current manual SPE procedure and GC-MS analysis.
Materials and Methods

Chemicals and reagents
High-performance liquid chromatography (HPLC)-grade water was purchased from Fisher Scientific (Fair Lawn, NJ). HPLC-grade methanol, reagent-grade formic acid, ammonium formate, and ammonium hydroxide were purchased from Sigma-Aldrich (St. Louis, MO). Reagent-grade hydrochloric acid was purchased from J.T. Baker (Philipsburg, NJ). Anhydrous isopropanol was purchased from Gallade Chemical (Escondido, CA). Omni-Solv methanol, ethyl acetate, acetonitrile, and potassium phosphate for the GC-MS procedure were purchased from EMD (Gibbstown, NJ). Pentafluoropropionic acid anhydride was purchased from Thermo Scientific (Rockford, IL).
Standards and controls
Stock methanolic solutions of 6-AM and 6-AM-d 6 were purchased from Cerilliant (Round Rock, TX). Each batch contained a 6-AM calibrator at 10 ng/mL, a low control at 4 ng/mL, a negative control at 0 ng/mL, and a high control at 90 ng/mL. The internal standard (IS) stock solution was formulated at 750 ng/mL. All standards, controls, and calibrators were spiked into certified drug-free urine obtained from Roche Diagnostics (Indianapolis, IN). Analyte concentrations for specimens and controls were calculated using the relative response of a singlepoint 6-AM calibrator at 10 ng/mL also containing the IS (6-AM-d 6 ) at 15 ng/mL prepared in certified drug-free urine.
Specimen and internal standard preparation
Each 10-mL aliquot of calibrator, control, and specimen contained 200 µL of IS stock solution (750 ng/mL in anhydrous ethanol) and 200 µL of 1.0 M pH 6.0 potassium phosphate buffer. For ease of preparation, a 10-mL specimen was split into two 5-mL portions for SPE-LC-MS-MS and GC-MS analysis. However, it should be noted that only 290 µL per injection of the latter portion was required for SPE-LC-MS-MS method.
Automated SPE system
The Symbiosis Pharma system includes a refrigerated specimen unit, autosampler, binary HPLC pumps, and an SPE automated cartridge exchange device (ACE), described in detail elsewhere (11) . The ACE system has two SPE cartridge clamps on both sides of the cartridge tray storage area. In the left clamp, a fresh cartridge was activated, equilibrated, loaded with specimen, and washed. The cartridge was transferred to the right clamp, where the cartridge contents were eluted directly onto the analytical column. Spark Holland Hysphere C8 EC-SE 10 cartridges (Spark Holland, Emmen, The Netherlands) were used for the SPE portion of the analysis, which contain 10-μm particle size end-capped silica-based C8 bonded phase material. Each cartridge was activated with 1 mL of acetonitrile at a flow rate of 5 mL/min. The cartridge was then equilibrated with 1 mL of 1% ammonium hydroxide in water at 5 mL/min. The system used 1 mL of 1% ammonium hydroxide in water to load the cartridge with 100 μL of specimen at 1 mL/min. The cartridge was washed with 1 mL 5% acetonitrile and 1% ammonium hydroxide in water at 5 mL/min. The cartridge contents were eluted by allowing the LC mobile phase (see LC-MS-MS chromatographic parameters) to flow through the SPE cartridge for 90 s. After elution of the SPE cartridge, the clamp and cartridge were flushed with 500 μL of 1% ammonium hydroxide in water.
The potential for carryover was mitigated by washing the autosampler loop and valve alternately with 700 μL of 40% acetonitrile/0.2% formic acid in water, 1400 μL of 40:40:10:10 (v/v/v/v) acetonitrile/methanol/isopropanol/water, and then reapplying the first solvent mixture. During the last two solvent applications, the valve mechanism was activated to effectively wet all surfaces.
LC parameters
Analytical chromatography was performed on a Waters (Milford, MA) Xbridge C8 column that was 2.1 mm in diameter × 50 mm long, with a 3.5-μm particle size. The analytical column was preceded by a Waters 2.1-mm × 10-mm guard column with sorbent that matched the analytical column and a 0.5-μm inline filter. A binary gradient system consisted of 0.05% formic acid/10 mM ammonium formate in water (solvent A) and 0.05% formic acid in methanol (solvent B). The gradient was performed according to the elution program described in Table I .
MS conditions
MS-MS detection was performed using a Waters Quattro Micro triple-quadrupole MS system in positive electrospray ionization mode. The 6-AM response was measured by multiple reaction monitoring (MRM) transitions of m/z 328.10 to m/z 193 and m/z 165. The first transition was used as the quantifying ion and the second transition as the qualifying ion. IS response was measured by the transition from m/z 334 to m/z 211. An MRM chromatogram of a standard containing 10 ng/mL of 6-AM and 15 ng/mL of 6-AM-d 6 is shown in Figure  1 .
Extraction and analysis by gas chromatography (GC)-MS
The specimen tubes were mixed thoroughly by vortex mixing and centrifuged for 5 min at 2500 rpm in a Silencer 2110 centrifuge (GFDM, Troy, MI) to remove any precipitate. All specimens were extracted using the Speedisk positive-pressure manifold (SPEware, San Pedro, CA) using SPEware Cerex cartridges (SPEware). The specimens were loaded onto the sorbent at 2-5 psi. The cartridges were successively washed with 2 mL of distilled water, 2 mL of 0.1 M hydrochloric acid, 2 mL of methanol, and 2 mL of ethyl acetate and then dried for 3 min at 20-25 psi. The cartridges were eluted into the tubes with 2 mL of 80:20:2 ethyl acetate/methanol/ammonium hydroxide. All the eluates were evaporated to dryness in an evaporation apparatus under a stream of 99.99% medical grade nitrogen gas (Westair, San Diego, CA) at 55-60°C. The eluates were derivatized using 50 µL of acetonitrile and 100 µL pentafluoropropionic acid anhydride and incubated for 30 min at 60°C. The derivatives were evaporated to dryness at room temperature under a stream of nitrogen, reconstituted with 50 µL ethyl acetate, and transferred to automated liquid sampler vials. The specimens were analyzed with an Agilent (Little Falls, DE) 6890 GC equipped with 7683 autosampler and an Agilent J&W DB-XLB capillary column (15 m × 0.25 mm × 0.25-µm film thickness) coupled to an Agilent 5975 mass selective detector operated in selected ion monitoring (SIM) mode. The injection port was held at 230°C in pulsed splitless mode (12 psi for 0.5 min), using helium as the carrier gas at constant flow 0.7 mL/min. The oven temperature was held initially at 165°C and increased to 250°C at 150°C/min and then held 290°C for 1.5 min. The transfer line temperature to the mass selective detector was maintained at 300°C.
Quantification of 6-AM in specimens and controls was calculated using the relative response of m/z 417 to that of m/z 414 from the 10 ng/mL calibrator multiplied by the cutoff level and the inverse response from the specimen. Qualifier ions for 6-AM were m/z 361 and m/z 473. These were required to be within ± 20% of those obtained from the cali- brator and the retention time to be ± 2% of the calibrator retention time.
Results and Discussion
The automated SPE-LC-MS-MS assay was evaluated for intrarun precision at 0, 4, 10, 12.5, 90, and 100 ng/mL (n = 5 at each level). The mean value and standard deviation at each control value were used to calculate the percent coefficient of variation (%CV). The %CV ranged from 1.0 to 4.4 (Table II) . Inter-run precision was evaluated at 10 ng/mL over nine analytical batches with five injections per batch (n = 45). The %CV was found to be 3.6. The limits of quantification (LOQ) and detection (LOD) for the automated SPE-LC-MS-MS method were determined by analyzing, in quintuplicate, six concentrations (0, 1, 2, 5, 10, and 15 ng/mL) of certified drugfree urine spiked with 6-AM. The LOQ was defined as the lowest level of analyte correctly quantifiable within ± 20% of the target concentration, with the qualifying ion ratio within ± 20% of the calibrator qualifying ion ratio. The LOD was the lowest level of analyte detectable that had only the qualifying ion ratio restriction applied. The LOQ and LOD were 2 ng/mL. The linearity of detector response was evaluated by analyzing concentrations of 6-AM prepared at 0, 4, 10, 12.5, 45, 90, and 100 ng/mL (n = 5 for each data point). The data were fit with a linear least-squares regression. The detector response was linear to 100 ng/mL with a slope of 0.93 and a correlation coefficient of 0.9983. Method specificity was investigated using compounds structurally similar to 6-AM. The potential interferences from codeine, morphine, oxycodone, oxymorphone, hydrocodone, hydromorphone, and norcodeine were analyzed at a concentration of 5000 ng/mL spiked into certified drug-free human urine. An identical set of these compounds were also spiked with 4.0 ng/mL of 6-AM and evaluated for their potential interference with quantification and/or analytical acceptability of the internal standard and/or the target analyte. None of the seven compounds interfered with the correct identification or quantification of 6-AM (Figure 2) . Figure 3 is a chart of the IS recovery for the interference specimens. IS recovery in all interference specimens was slightly greater than that of the calibration standard (15 ng/mL). Recoveries ranged from 16.0 to 18.0 ng/mL with a %CV of 0.64. 6-AM recovery ranged from 3.4 to 4.0 ng/mL, all within the ± 20% acceptable range of 3.2 to 4.8 ng/mL.
The potential for carryover was evaluated by the extraction and injection of a 200 ng/mL 6-AM control followed by three certified drug-free human urine specimens containing only the IS. No carryover was detected in any of the three specimens following the control.
The potential for ion suppression or enhancement was first evaluated using post column infusion as described by Bonfiglio et al. (15) . Certified drug-free human urine was extracted and eluted onto the analytical column after which 6-AM (100 ng/mL) was infused at a flow rate of 40 μL/min prior to the detector inlet. There was no ion suppression of 6-AM signal noted during the analytical run time. In addition, the method described by Matuszewski and co-workers (16) was applied at the cutoff level to estimate the possibility of matrix interference. This required fortification of the mo- bile phase with analyte and IS for LC-only response. This response was then compared with pre-and post-extraction spikes of analyte and IS into the eluent of 10 different 6-AM negative urine specimens. As defined by Matuszewski, the matrix effect (ME), recovery effect (RE), and process efficiency (PE) were calculated as 100.4, 94.5, and 94.9 for the IS and 100.4, 105.9, and 106.3 for 6-AM, respectively. The %CV for the ME set of specimens was 4.0 for the IS and 3.0 for 6-AM. The ME values of 100.4 for IS and 6-AM indicate that there is no significant matrix effect across the 10 lots of negative urine used in this experiment. It is not remarkable that the deuterated IS performs identically with respect to electrospray ionization as the analyte because they are chemically identical. The cutoff and internal standard concentrations for 6-AM are low enough that there is significant overhead in the ionization chamber unless there is an interferant present. A comparative study of 41 specimens previously found to contain 6-AM was performed in parallel with the previously validated GC-MS and the SPE-LC-MS-MS method. Specimens that exceeded the assay limit of linearity (100 ng/mL) were diluted with certified drug-free human urine and reanalyzed. The concordance of the data generated by both methods was excellent with a correlation coefficient of 0.9951 and a slope of 0.93 ( Figure 4) . Importantly, both methods produced the same number of positive specimens and negative specimens at the DoD and HHS 10 ng/mL cutoff concentration.
The percent deviation of the MS-MS qualifying ion ratio (ratio of the areas obtained from the transition of m/z 328.1 to m/z 165.0 to that of m/z 328.1 to m/z 211) for the authentic human urine specimens were plotted in Figure 5 . As required by the DoD Standard Operating Procedure Manual, all ratios were within ± 20 percent of that obtained for the calibrator.
The percent increase or decrease of the IS response of each authentic human urine specimen relative to that obtained from the calibrator is shown in Figure 6 . In every case, the data are consistent with National Laboratory Certification Program acceptance criterion that requires an IS response within one-half and two times of the calibrator IS response.
Conclusions
The DoD has a history of commitment to increasing the efficiency, cost effectiveness, and forensic integrity of drug urine analysis testing that requires an integrated approach to specimen preparation, handling, and analysis. The automated SPE-LC-MS-MS procedure eliminates most of the specimen handling events subsequent to the specimen pour-up, such as specimen transfer, various label transfers, and chain of custody events. These issues in manual procedures are potential causes of rework and sample misidentification. The automated 6-AM method provided comparable results to the GC-MS method in regards to instrument run time, linearity, precision, accuracy, LOD, and LOQ. The SPE-LC-MS-MS provides a 50% reduction in the amount of time and a 50-fold reduction in the amount of urine required to take the specimens from extraction through analysis and reporting. Other benefits include time savings, as the instrument eliminates the need for offline SPE, derivatization, and manual transfer of specimens. The only non-automated step in this procedure is the addition of IS. However, as communicated previously (11), these steps may also be automated. 
